[go: up one dir, main page]

MX377426B - EXTENDED-RELEASE FORMULATIONS OF COLCHICINE AND METHODS OF USING THE SAME. - Google Patents

EXTENDED-RELEASE FORMULATIONS OF COLCHICINE AND METHODS OF USING THE SAME.

Info

Publication number
MX377426B
MX377426B MX2015014656A MX2015014656A MX377426B MX 377426 B MX377426 B MX 377426B MX 2015014656 A MX2015014656 A MX 2015014656A MX 2015014656 A MX2015014656 A MX 2015014656A MX 377426 B MX377426 B MX 377426B
Authority
MX
Mexico
Prior art keywords
colchicine
extended
methods
same
release
Prior art date
Application number
MX2015014656A
Other languages
Spanish (es)
Other versions
MX2015014656A (en
Inventor
Susanne Riel
Original Assignee
Murray And Poole Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Murray And Poole Enterprises Ltd filed Critical Murray And Poole Enterprises Ltd
Publication of MX2015014656A publication Critical patent/MX2015014656A/en
Publication of MX377426B publication Critical patent/MX377426B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate- release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Method of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
MX2015014656A 2013-04-16 2014-04-16 EXTENDED-RELEASE FORMULATIONS OF COLCHICINE AND METHODS OF USING THE SAME. MX377426B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361812514P 2013-04-16 2013-04-16
EP13194505 2013-11-26
PCT/IB2014/001201 WO2014170755A2 (en) 2013-04-16 2014-04-16 Sustained-release formulations of colchicine and methods of using same

Publications (2)

Publication Number Publication Date
MX2015014656A MX2015014656A (en) 2016-03-01
MX377426B true MX377426B (en) 2025-03-10

Family

ID=49683519

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015014656A MX377426B (en) 2013-04-16 2014-04-16 EXTENDED-RELEASE FORMULATIONS OF COLCHICINE AND METHODS OF USING THE SAME.
MX2020012310A MX2020012310A (en) 2013-04-16 2015-10-16 Sustained-release formulations of colchicine and methods of using same.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012310A MX2020012310A (en) 2013-04-16 2015-10-16 Sustained-release formulations of colchicine and methods of using same.

Country Status (19)

Country Link
US (6) US20160081936A1 (en)
EP (1) EP2986280B1 (en)
JP (1) JP6480420B2 (en)
KR (1) KR102271048B1 (en)
CN (1) CN105307643A (en)
AU (4) AU2014255434B2 (en)
BR (1) BR112015026418B1 (en)
CA (1) CA2909370A1 (en)
CL (1) CL2015003072A1 (en)
EA (1) EA037375B1 (en)
MA (1) MA38576B2 (en)
MX (2) MX377426B (en)
MY (2) MY207496A (en)
PL (1) PL2986280T3 (en)
PT (1) PT2986280T (en)
SG (1) SG11201508571WA (en)
SI (1) SI2986280T1 (en)
WO (1) WO2014170755A2 (en)
ZA (1) ZA201507723B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056810T2 (en) 2012-11-02 2022-03-28 Murray & Poole Entpr Ltd Treatment or prevention of cardiovascular events via the administration of colchicine
ES2870718T3 (en) * 2013-04-16 2021-10-27 Murray & Poole Entpr Ltd Colchicine sustained-release formulation and methods for establishing the same
EP2986280B1 (en) * 2013-04-16 2021-03-17 Murray & Poole Enterprises, Ltd. Sustained-release formulations of colchicine and methods of using same
WO2016166732A1 (en) * 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
EP3641726B1 (en) * 2017-06-23 2025-11-05 NordicCan A/S Cannabinoid pouch
US10226423B1 (en) 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
CA3089781A1 (en) * 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
CN110448527B (en) * 2019-09-23 2021-11-26 杭州百诚医药科技股份有限公司 Colchicine oral solution and prescription composition thereof
GB201913827D0 (en) * 2019-09-25 2019-11-06 Cape Peninsula Univ Of Technology Sustained Release Formulation Containing Aspalathus linearis Extract
KR102112456B1 (en) 2019-11-13 2020-05-19 주식회사 에이스바이오메드 Combination formulation containing colchicine for treatment or enhancing the therapy of liver disease
CA3161620A1 (en) 2019-11-15 2021-05-20 Institut De Cardiologie De Montreal Methods for using low-dose colchicine after myocardial infarction
CN111150702B (en) * 2019-12-04 2021-06-22 复旦大学 A kind of gel drug sustained-release preparation and preparation method and application thereof
WO2021145699A1 (en) 2020-01-17 2021-07-22 한국생명공학연구원 Composition for treating skin diseases, comprising colchicine
KR20210095249A (en) 2020-01-22 2021-08-02 주식회사 에이스바이오메드 Combination formulation containing colchicine for treatment or enhancing the therapy of liver disease
KR102150821B1 (en) 2020-01-22 2020-09-03 주식회사 에이스바이오메드 Combination formulation containing colchicine for treatment or enhancing the therapy of liver disease
KR102177781B1 (en) 2020-04-27 2020-11-12 주식회사 에이스바이오메드 Combination formulation containing colchicine, UDCA and DDB for treatment or enhancing the therapy of liver disease
EP4262771A4 (en) * 2020-12-15 2025-03-05 Romeg Therapeutics LLC Methods and compositions for treating pericarditis
CN113476603B (en) * 2021-07-08 2022-05-20 中南大学 Magnetic nanoparticle wrapped by erythrocyte membrane as well as preparation method and application of magnetic nanoparticle
CN118717741A (en) * 2024-01-15 2024-10-01 华中科技大学同济医学院附属协和医院 Application of colchicine in the preparation of a drug for increasing the thickness of the fibrous cap of coronary artery plaques
KR102870211B1 (en) * 2024-06-11 2025-10-16 (주)알피바이오 Long-acting formulation composition

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
SE9003904D0 (en) * 1990-12-07 1990-12-07 Astra Ab METHOD FOR THE MANUFACTURE OF A PHARMACEUTICAL DOSAGE FORM
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
JP2000034224A (en) * 1998-05-11 2000-02-02 Freunt Ind Co Ltd Sustained-release tablet, additive composition thereof and method for producing the same
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
CA2394222A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
IL157634A0 (en) 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006063091A2 (en) 2004-12-06 2006-06-15 Ronald Freudenberger Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity
US20060171948A1 (en) 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
US20060286108A1 (en) 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
CN1748671A (en) 2005-08-30 2006-03-22 孔庆忠 Slow releasing injection containing anti-mitosis medicine
CN1939290A (en) 2005-09-29 2007-04-04 陆宪光 Medical usage of colchicine and its derivative
WO2007048004A2 (en) 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
JP2009542583A (en) 2006-06-02 2009-12-03 バイオシーク インコーポレイティッド Methods for identifying drugs for the prevention of restenosis and their use
WO2007141298A1 (en) * 2006-06-09 2007-12-13 Schwarz Pharma Ag Stabilized pharmaceutical compositions comprising fesoterodine
PT103884A (en) * 2006-11-17 2008-05-19 Astrazeneca Ab PROLONGED RELEASE COMPOSITIONS AND METHODS FOR THEIR PREPARATION
WO2008131192A2 (en) 2007-04-18 2008-10-30 The Trustees Of Columbia University In The City Of New York Crystalline cholestrol and prevention of atherosclerosis
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
CN101485638A (en) * 2008-01-18 2009-07-22 普尔药物科技开发（深圳）有限公司 Colchicine double-layer osmotic pump controlled release tablets and preparation method thereof
CN101485637B (en) * 2008-01-18 2011-03-30 普尔药物科技开发（深圳）有限公司 Colchicine Matrix Controlled Release Tablets or Capsules
WO2009097450A1 (en) 2008-01-30 2009-08-06 Dexcom. Inc. Continuous cardiac marker sensor system
CN101536990A (en) * 2008-03-18 2009-09-23 普尔药物科技开发（深圳）有限公司 Colchicines gastric floating sustained-release tablet and method for preparing same
EP2262786A4 (en) 2008-04-15 2014-07-09 Takeda Pharmaceuticals Usa Inc Colchicine solid-state forms; methods of making; and methods of use thereof
DE102008047910A1 (en) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CN101732274A (en) * 2008-11-19 2010-06-16 普尔药物科技开发（深圳）有限公司 Colchicine bilayer sustained-release tablet and preparing method thereof
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
WO2010103365A2 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
US20110046228A1 (en) 2009-08-20 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for administration of colchicine with grapefruit juice
US20110046227A1 (en) 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
CA2780939C (en) * 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Bilayer tablet formulations
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2836209A4 (en) 2012-04-13 2015-11-25 Cymabay Therapeutics Inc METHOD OF TREATING HYPERURICEMIA USING HALOFENATE OR HALOFENIC ACID AND AN ANTI-INFLAMMATORY AGENT IN PATIENTS WITH DROP
HUE056810T2 (en) 2012-11-02 2022-03-28 Murray & Poole Entpr Ltd Treatment or prevention of cardiovascular events via the administration of colchicine
EP2986280B1 (en) * 2013-04-16 2021-03-17 Murray & Poole Enterprises, Ltd. Sustained-release formulations of colchicine and methods of using same
CN110148563A (en) * 2019-05-23 2019-08-20 武汉新芯集成电路制造有限公司 A kind of semiconductor devices and its manufacturing method

Also Published As

Publication number Publication date
PT2986280T (en) 2021-05-07
US10610488B2 (en) 2020-04-07
MX2015014656A (en) 2016-03-01
AU2019201048B2 (en) 2021-01-28
US10105319B2 (en) 2018-10-23
CL2015003072A1 (en) 2016-09-23
SI2986280T1 (en) 2021-08-31
AU2019201048A1 (en) 2019-03-07
WO2014170755A3 (en) 2015-02-19
US20200030240A1 (en) 2020-01-30
KR102271048B1 (en) 2021-06-30
WO2014170755A2 (en) 2014-10-23
AU2014255434A1 (en) 2015-11-05
US11648206B2 (en) 2023-05-16
AU2014255434B2 (en) 2018-11-08
BR112015026418A2 (en) 2017-07-25
EP2986280B1 (en) 2021-03-17
PL2986280T3 (en) 2021-10-25
KR20150143725A (en) 2015-12-23
MA38576A1 (en) 2017-05-31
JP6480420B2 (en) 2019-03-13
CA2909370A1 (en) 2014-10-23
AU2020294268B2 (en) 2024-05-02
MY207496A (en) 2025-02-28
AU2020294268A1 (en) 2021-01-28
SG11201508571WA (en) 2015-11-27
EP2986280A2 (en) 2016-02-24
US20150094322A1 (en) 2015-04-02
US20150094323A1 (en) 2015-04-02
JP2016521270A (en) 2016-07-21
MA38576B2 (en) 2020-02-28
BR112015026418B1 (en) 2022-10-04
CN105307643A (en) 2016-02-03
EA037375B1 (en) 2021-03-22
US20230414521A1 (en) 2023-12-28
US20190054028A1 (en) 2019-02-21
US10130585B2 (en) 2018-11-20
ZA201507723B (en) 2023-05-31
EA201501024A1 (en) 2016-08-31
MY198452A (en) 2023-08-29
US20160081936A1 (en) 2016-03-24
MX2020012310A (en) 2021-01-29
AU2024205185A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MX377426B (en) EXTENDED-RELEASE FORMULATIONS OF COLCHICINE AND METHODS OF USING THE SAME.
MX2009001711A (en) Sustained-release formulations of topiramate.
ECSP10010548A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
MX377340B (en) SOLID SOLUTION COMPOSITIONS AND USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES.
MX2018002462A (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition.
MX2020011100A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF PPAR AGONISTS.
MX2017014994A (en) ORAL SOLID FORMULATION CONTAINING IRINOTECHAN AND METHOD OF PREPARATION OF THE SAME.
UA107550C2 (en) ESTRA-1,3,5 (10), 16-TETRAEIN-3-CARBOXAMAMID DERIVATIVES, THE METHODS OF THEIR PREPARATION, THE PHARMACEUTICAL PREPARATIONS THEREOF, AND THEIR USE
UY35091A (en) MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
ES2850277R1 (en) Pharmaceutical administration compositions and uses thereof
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
MX2020004107A (en) DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USE THEREOF.
BR112017009510A2 (en) compositions comprising cyclosporine
PH12015502556A1 (en) Modified release formulation
MX2019005925A (en) LIQUID ALLERGEN COMPOSITIONS AND METHODS FOR THE PREPARATION OF THE SAME.
MX2023006235A (en) COMPOSITIONS FOR ADMINISTRATION OF DRUGS AND METHODS OF USE THEREOF.
EP3773654C0 (en) PHARMACEUTICAL ACTIVE COMPOSITIONS AND ASSOCIATED METHODS
EP4013418A4 (en) DERMAL PHARMACEUTICAL URACIL FORMULATION
MX391191B (en) EXTENDED-RELEASE COMPOSITIONS OF ONAPRISTONE AND METHODS.
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
EP3735238A4 (en) STABLE ORAL PHARMACEUTICAL COMPOSITION OF IRON CITRATE
EA201590752A1 (en) PYRAMIDINDION DERIVATIVES PREPARATIONS
EP3921322C0 (en) PHOSPHOR-IMIDAZOQUINOLINE-AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
MX2018012223A (en) LIQUID FORMULATIONS OF PHOSPHAPLATIN.
MX393915B (en) NEW ORAL FORMULATIONS OF BELINOSTAT.

Legal Events

Date Code Title Description
FG Grant or registration